Please login to the form below

Not currently logged in

hepatitis B

This page shows the latest hepatitis B news and features for those working in and with pharma, biotech and healthcare.

Long-serving R&D head Bischofberger to leave Gilead

Long-serving R&D head Bischofberger to leave Gilead

During his tenure he oversaw the launch of a raft of HIV and hepatitis C and B therapies. ... McHutchison has been at Gilead since 2010, joining the company from Duke University Medical Center, and has been a key figure in the company hepatitis

Latest news

More from news
Approximately 6 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    Hepatitis C virus treatments like Maviret from AbbVie, which cures people with hard-to-treat genotype 3 after an 8. ... This is the route the NHS in the UK has taken with innovative hepatitis C treatments; it will only pay for the medication if a patient

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    153. NeuroVive / OnCore. Licence and collaboration. NVP018 an oral sangamide-based 2nd generation cyclophilin inhibitor for hepatitis B.

  • Case study: Confront hepatitis Case study: Confront hepatitis

    Challenge. 500 million people globally are living with either chronic hepatitis B or C - while this is higher than those with HIV or any cancer, the disease is hugely underfunded, with ... Client verdict. Charles Gore, president of the World Hepatitis

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....